Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Acerta Pharma
Oss, Netherlandsacerta-pharma.com ↗
- Ownership
- Private
- Employees
- ~200
- Development stage
- Other
01
Overview
Acerta Pharma's flagship drug Calquence (acalabrutinib) has been approved by the FDA for the treatment of mantle cell lymphoma (2017) and chronic lymphocytic leukemia (2019). The drug is now used to treat tens of thousands of patients worldwide and generated more than $2 billion in revenue in 2022[4][5].
- Therapeutic areas
- OncologyHematology
- Modalities
- Small molecule drugsMonoclonal antibodies
- Industry
- Biotech
02
Partnerships
Ascentage PharmaForty Seven Inc.
Beyond the preview
Go deeper on Acerta Pharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Acerta Pharma.